In antral mucous cells, acetylcholine (ACh, 1 M) activates Ca 2ϩ -regulated exocytosis, consisting of an initial peak that declines rapidly (initial transient phase) followed by a second slower decline (late phase) lasting during ACh stimulation. The addition of 8-bromo-cGMP (8-BrcGMP) enhanced the initial phase, which was inhibited by the protein kinase G (PKG) inhibitor guanosine 3=,5=-cyclic monophosphorothoiate, ␤-phenyl-1,N 2 -etheno-8-bromo, Rp-isomer, sodium salt (Rp-8-BrPETcGMPS, 100 nM). However, Rp-8-BrPETcGMPS produced a delayed, but transient, increase in the exocytotic frequency during the late phase that was abolished by a protein kinase A (PKA) inhibitor (PKI-amide), suggesting that Rp-8-BrPETcGMPS accumulates cAMP. The cGMP-dependent phosphodiesterase 2 (PDE2), which degrades cAMP, may exist in antral mucous cells. The PDE2 inhibitor BAY-60-7550 (250 nM) mimicked the effect of Rp-8-BrPETcGMPS on ACh-stimulated exocytosis. Measurement of the cGMP and cAMP contents in antral mucosae revealed that ACh stimulates the accumulation of cGMP and that BAY-60-7550 accumulates cAMP similarly to Rp-8-BrPETcGMPS during ACh stimulation. Analyses of Western blot and immunohistochemistry demonstrated that PDE2A exists in antral mucous cells. In conclusion, Rp-8-BrPETcGMPS accumulates cAMP by inhibiting PDE2 in AChstimulated antral mucous cells, leading to the delayed, but transient, increase in the frequency of Ca 2ϩ -regulated exocytosis. PDE2 may prevent antral mucous cells from excessive mucin secretion caused by the cAMP accumulation.
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acetylcholine; guanosine 3=,5=-cyclic monophosphate; adenosine 3=,5=-cyclic monophosphate; gastric; mucin secretion GASTRIC MUCINS, WHICH ARE high-molecular-weight glycoproteins that protect the gastric mucosa from acid-peptic injury, are stored in intracellular granules and secreted to the lumen by Ca 2ϩ -regulated exocytosis. Ca 2ϩ -regulated exocytosis in antral mucous cells consists of three biochemically distinct steps: docking, priming, and fusion. The priming step is regulated by ATP, and the fusion step is regulated by Ca 2ϩ (12, 20, 23) . In antral mucous cells, Ca 2ϩ -regulated exocytosis has characteristic features of frequency: an initial peak that declines rapidly (initial phase or initial transient phase) followed by a second slower decline (late phase) lasting during acetylcholine (ACh) stimulation. The initial phase, which is transient and has a high frequency of exocytotic events, is caused by an immediate fusion of the primed granules (the pool of releasable granules), and the late phase, which has a low frequency of exocytotic events, is caused by a fusion of granules that are in the process of priming (10) .
In antral mucous cells, Ca 2ϩ -regulated exocytosis is activated by ACh and is modulated by many substances, such as cAMP, cGMP, arachidonic acid (AA), and intracellular Cl Ϫ (3, 4, 10, 11, 14 -18 ). An accumulation of cAMP, which accelerates the priming step and the fusion step, also significantly increases the frequency of the initial phase in Ca 2ϩ -regulated exocytotic events. However, cGMP accelerates the priming step of Ca 2ϩ -regulated exocytosis, leading to an increase in the frequency of the initial phase; the cGMP-induced enhancement of the initial phase was not affected by protein kinase A (PKA) inhibitors (PKI-amide and H-89) (14) .
Conversely, accumulation of cGMP or cAMP is modulated by cyclic nucleotide phosphodiesterases (PDEs) in many cell types. There are many PDE subtypes. The PDE subtype PDE2 is a cGMP-dependent enzyme that degrades the phosphodiester bond of cAMP (2, 5, 6) . However, at present, there are no reports showing that PDE2 controls cAMP accumulation in antral mucous cells.
In antral mucous cells, we used the protein kinase G (PKG) inhibitor guanosine 3=,5=-cyclic monophosphorothoiate, ␤-phenyl-1,N 2 -etheno-8-bromo, Rp-isomer, sodium salt (Rp-8-BrPETcGMPS), to inhibit the 8-bromo-cGMP (8-BrcGMP)-induced enhancement of the initial phase in Ca 2ϩ -regulated exocytotic events. Rp-8-BrPETcGMPS actually depressed the initial phase of Ca 2ϩ -regulated exocytotic events enhanced by 8-BrcGMP but produced a delayed, but transient, increase during the second slower decline. An inhibitor of PKG, Rp-8-BrPETcGMPS, is unlikely to induce the delayed and transient increase in the frequency of the Ca 2ϩ -regulated exocytotic events because the inhibition of PKG decreases the number of primed granules (the pool of releasable granules). Our hypothesis is that an inhibitor of PKG inhibits cAMP degradation mediated via PDE2, leading to cAMP accumulation. The goal of this study is to confirm this hypothesis.
MATERIALS AND METHODS
Solutions and chemicals. Solution I contained the following (in mM): 121 NaCl, 4.5 KCl, 25 NaHCO 3, 1 MgCl2, 1.5 CaCl2, 5 Na-HEPES, 5 H-HEPES, and 5 glucose. To prepare Ca 2ϩ -free solutions, CaCl 2 was removed from solution I, and 1 mM EGTA was added. The pH of the solutions was adjusted to 7.4 by adding HCl (1 M). The solutions were aerated with a gas mixture (95% O 2 and 5% CO 2) at 37°C. ACh was purchased from Daiichi Pharmaceuticals (Osaka, Japan). Collagenase (for cell dispersion, 180 -220 U/mg) and BSA were purchased from Wako Pure Chemical Industries (Osaka, Japan). 8-BrcGMP and Rp-8-BrPETcGMPS were purchased from Sigma (St. Louis, MO).
]riazin-4(1H)-one (BAY-60-7550) and PKI-amide (an inhibitor of PKA) were from Biomol (Plymouth Meeting, PA). All reagents were dissolved in dimethyl sulfoxide (DMSO) and were prepared to their final concentrations immediately before the experiments. The DMSO concentration did not exceed 0.1%, and this concentration had no effect on cell volume, intracellular Ca 2ϩ concentration ([Ca 2ϩ ]i), intracellular Cl Ϫ concentration, or frequency of exocytotic events in antral mucous cells (3, 4, 10, 11, 14 -18) .
Cell preparations. Hartley strain male guinea pigs weighing ϳ250 g were purchased from SLC (Shizuoka, Japan) and fed standard pelleted food and water. The guinea pigs were anesthetized by intraperitoneal injection of pentobarbital sodium (70 mg/kg), after which they were killed by cervical dislocation. The procedures for the cell preparation have been described previously (3, 4, 10, 11, 14, 16 -18) . Briefly, the gastric antrum was excised, and the mucosal layer was stripped from the muscle layer in cooled saline (4°C) using glass slides. The stripped antral mucosa was minced and then incubated in solution I containing 0.1% collagenase and 4% BSA for 12 min at 37°C. The digested mucosa was filtered through nylon mesh with a pore size of 300 m square and washed three times. The cells were resuspended in solution I containing 4% BSA (4°C). The cell suspension was stored at 4°C and used in the experiments within 3 h.
The procedures and protocols for these experiments were reviewed and approved by the Animal Research Committee of Osaka Medical College, and the experiments were performed in accordance with the guidelines of this committee and the Guiding Principles for the Care and Use of Animals in the Field of Physiological Sciences (Physiological Society of Japan).
Observation of exocytosis. The isolated antral mucous cells were mounted on a cover slip precoated with neutralized Cell-Tak (BectonDickinson Labware, Bedford, MA) for secure attachment of the cells. The cover slip with the cells was set in a perfusion chamber mounted on the stage of a differential interference contrast microscope (BX50Wi; Olympus, Tokyo, Japan), which was connected to a videoenhanced contrast system (ARGUS-20; Hamamatsu Photonics, Hamamatsu, Japan) (3, 4, 10, 11, 14, 16 -18) . Images were recorded continuously using a video recorder. The experiments were performed at 37°C. The volume of the perfusion chamber was ϳ20 l, and the rate of perfusion was 200 l/min. Exocytotic events, which were detected as rapid changes in the light intensity of the granules (3, 4, 10, 11, 14, 16 -18) , were counted in two to four cells every 30 s and were normalized to the number of cells (events·cell Ϫ1 ·30 s Ϫ1 ). The frequency of exocytotic events in 4 -10 experiments was expressed as the mean Ϯ SE. In the statistical comparisons of the results obtained from the experiments, the frequencies of the initial and late phases were used. The frequency at 1 min from the start of ACh stimulation was used for the frequency of the initial phase throughout the experiments. For the frequency of the late phases, in the control experiment, the frequency 4 min after the ACh stimulation was used, whereas, in the experiments using Rp-8-BrPETcGMPS or BAY-60-7550, the highest frequency within 3-6 min after the ACh stimulation was used.
Western blot analysis. Western blot analysis for PDE2 was carried out using antral mucosa and brain of guinea pigs. The procedures for protein extraction and Western blot have already been mentioned in our previous report (15) . The antibody used for detection was anti-PDE2A antibody (TA502320; OriGene). The protein band was visualized using an enhanced chemiluminescence reagent (Chemi-Lumi One L; Nacalai Tesque, Kyoto, Japan) and captured using a Luminoimage analyzer (LAS 3000; Fuji Film, Tokyo, Japan).
Immunohistochemical examination. The antrum was fixed in 10% formalin buffered with 150 mM phosphate for 24 h, dehydrated in a graded series of ethanol concentrations, and embedded in paraffin, in accordance with a standard protocol. Some sections were then stained with hematoxylin and eosin (HE). Other sections were immunostained for PDE2A. Briefly, 5-m-thick deparaffinized sections were treated by heat-mediated epitope retrieval (10 mM citrate buffer, pH 6.0) at full pressure for 15 min at 121°C. The sections were incubated with 0.3% H2O2 in methanol for 10 min to block any endogenous peroxidases and then incubated with a primary antibody for 1 h at room temperature in a moist chamber. The envision polymer (Dako, Carpinteria, CA) was added, and the reaction mixture was incubated for 60 min. Color development was performed for 5-8 min using 0.02% 3,3=-diaminobenzidine tetrahydrochloride (Dako) in 0.05 M Tris·HCl (pH 7.6) with 0.005% H2O2. Finally, the sections were counterstained with hematoxylin.
Measurement of [Ca 2ϩ ]i. We measured [Ca 2ϩ ]i using the isolated antral mucous cells that were loaded with fura 2. The fluorescence ratio (fluorescence at 340 nm/fluorescence at 380 nm) was measured using the image analysis system (Acua Cosmos; Hamamatsu photonicsn) (excitation 340 and 380 nm, emission 510 nm). Previous reports have shown the procedure for [Ca 2ϩ ]i measurement (4, 10, 14, 16 -18) .
Measurement of cGMP and cAMP. The stripped antral mucosa from each animal was cut into three samples. The stripped mucosa was incubated for 10 min at 37°C in the control solution (10 ml) aerated with 95% O 2 and 5% CO2 (control incubation). In cGMP measurements, following the control incubation, the stripped mucosa was incubated with DMSO (10 l) or stimulated with ACh (1 M) for 10 min. After the stimulations, the antral mucosa was immediately frozen in liquid nitrogen and lyophilized at Ϫ80°C for 24 h. In cAMP measurement, following the control incubation, the stripped mucosa was stimulated with DMSO (10 l), ACh (1M), ACh (1 M) plus Rp-8-BrPETcGMPS (500 nM), or ACh (1 M) plus BAY-60-7550 (100 nM). Stimulation periods used were 1, 5, and 10 min. After the stimulations, the antral mucosa was immediately frozen in liquid nitrogen and lyophilized at Ϫ80°C for 24 h. The lyophilized, antral mucosae were weighed, and their cAMP or cGMP contents were measured using a cAMP EIA kit (Cayman Chemical) or a cGMP EIA kit (Amersham International, Little Chalfont, UK). The cGMP and cAMP content was expressed as picomoles per gram of dry tissue weight (10, 11) .
Measurement of prostaglandin E 2 concentration. The stripped antral mucosa was weighed and then stored in solution I at 4°C before the start of experiments (30 -60 min). After a 3-min warm-up period, the stripped antral mucosa was incubated in the control solution (10 ml) aerated with 95% O 2 and 5% CO2 for 10 min at 37°C, before ACh stimulation, and then incubated for a further 15 min. In the vehicle control group, DMSO (10 l) was added instead of ACh (1 or 10 M). Five hundred microliters of the incubation solution were transferred to a microtube immediately before and 15 min after ACh stimulation. The microtube containing the sample was immediately cooled on ice and stored at Ϫ30°C until the PGE 2 concentration measurements. PGE2 concentrations were measured using a PGE2 EIA kit (Cayman Chemical), and PGE2 contents were expressed as micrograms per gram weight of tissue (4, 16, 17) . The amount of PGE2 released was calculated from the difference between the values before and 15 min after ACh stimulation.
Statistical analysis. Statistical significance between the means was assessed using Student's paired or unpaired t-tests, or ANOVA, as appropriate. Differences were considered significant at P Ͻ 0.05.
RESULTS
The ACh concentration used for stimulation was 1 M throughout the experiments.
The cGMP content. The cGMP content was measured in unstimulated and ACh-stimulated stripped antral mucosae. Stimulation with ACh increased cGMP content roughly double in the antral mucosae (Fig. 1) . The cGMP content of unstimulated antral mucosae was 6.7 Ϯ 0.1 pmol/g dry tissue (n ϭ 3) and that of the ACh-stimulated antral mucosae was 12.2 Ϯ 2.4 pmol/g dry tissue (n ϭ 3). Thus, ACh stimulated an accumulation of cGMP in the antral mucosa.
Effects of cGMP on Ca 2ϩ -regulated exocytosis. The effect of ACh on Ca 2ϩ -regulated exocytosis of antral mucous cells has already been reported in the previous reports (3, 4, 10, 11, 14 -18) . In unstimulated antral mucous cells, no exocytotic events occurred. ACh induced a biphasic increase in the frequency of exocytotic events: an initial peak that declines rapidly (initial phase or initial transient phase) followed by a second slower decline (late phase) lasting during ACh stimulation. The frequency of the initial phase (1 min after the start of the stimulation) was 10.0 Ϯ 0.9 events·cell Ϫ1 ·30 s Ϫ1 (n ϭ 4) and that of the late phase (4 min after the start of the stimulation) was 1.7 Ϯ 0.2 events·cell Ϫ1 ·130 s Ϫ1 (n ϭ 4) ( Fig. 2A) . The previous study demonstrated that 8-BrcGMP enhances the initial phase of Ca 2ϩ -regulated exocytosis in antral mucous cells (14) . In this study, we confirmed the same effects of 8-BrcGMP on the frequency of ACh-stimulated exocytotic events. Antral mucous cells were treated with 100 M 8-BrcGMP for 3 min and then stimulated with ACh. Prior treatment of 8-BrcGMP enhanced the initial phase stimulated with ACh ( Fig. 2A) . The frequencies of the initial and late phases were 18.1 Ϯ 0.7 and 1.8 Ϯ 0.1 events·cell Ϫ1 ·30 s Ϫ1 (n ϭ 4), respectively. The effects of a PKG inhibitor (Rp-8-BrPETcGMPS) on the 8-BrcGMPenhanced initial phase were examined. Antral mucous cells were treated with 500 nM Rp-8-BrPETcGMPS for 5 min and then with 8-BrcGMP plus Rp-8-BrPETcGMPS for a further 3 min. Stimulation with ACh biphasically increased the frequency of exocytotic events. In the presence of Rp-8-BrPETcGMPS, 8-BrcGMP did not enhance the initial phase, and rather the frequency of the initial phase was reduced to about 66% (6.6 Ϯ 0.3 events·cell
, n ϭ 5) of that seen in the absence of 8-BrcGMP (Fig. 2, A and B) . This result is consistent with that shown in Fig. 1 , in which ACh alone stimulates cGMP accumulation (Fig. 1) . The accumulation of cGMP increases the frequency of the initial phase in ACh-stimulated antral mucous cells (Fig. 2) . However, Rp-8-BrPETcGMPS induced a delayed, but , n ϭ 5, at 4.5 min from the start of ACh stimulation) during the late phase (Fig. 2B) . Figure 2C shows the frequency of exocytotic events from 3 to 6 min after the start of ACh stimulation (the late phase). In the presence of Rp-8-BrPETcGMPS, a delayed, but transient, increase in the frequency of exocytotic events started after 3.5 min from the start of ACh stimulation.
Effects of Rp-8-BrPETcGMPS on Ca 2ϩ -regulated exocytosis. We examined the effects of Rp-8-BrPETcGMPS on the frequency of exocytotic events stimulated by ACh alone. Antral mucous cells were treated with 500 nM Rp-8-BrPETcGMPS for 5 min before ACh stimulation. The treatment of Rp-8-BrPETcGMPS decreased the frequency of the initial phase by 30% but induced a delayed and transient increase in the frequency of the late phase (Fig. 3A) . The frequencies of the initial and late phases were 6.9 Ϯ 0.2 and 3.1 Ϯ 0.6 events·cell 
·30 s
Ϫ1 (n ϭ 10) (Fig. 3B) . Thus the delayed and transient increase was not caused by the cumulative effect of Rp-8-BrPETcGMPS.
In a Ca 2ϩ -free solution, we examined the effects of Rp-8-BrPETcGMPS on the frequency of ACh-stimulated exocytotic events (Fig. 3C) . Stimulation with ACh induced a small transient increase in the frequency of the initial phase (3.8 Ϯ 0.4 events·cell
Ϫ1

·30 s
Ϫ1
, n ϭ 5) at 1 min after ACh stimulation without any late phase. The prior treatment of Rp-8-BrPETcGMPS slightly decreased the frequency of the initial phase (2.9 Ϯ 0.6 events·cell Ϫ1 ·30 s Ϫ1 , n ϭ 4) at 1 min after ACh stimulation but did not induce any increase in the frequency of the late phase, suggesting that an increase in [Ca 2ϩ ] i is essential for the effects of Rp-8-BrPETcGMPS in the late phase.
Effects of PKI-amide (a PKA inhibitor) on Ca 2ϩ
-regulated exocytosis. To examine whether Rp-8-BrPETcGMPS acts via increased cAMP, we examined the effects of a PKA inhibitor (PKI-amide). Antral mucous cells were treated with 1 M PKIamide for 5 min and then with 500 nM Rp-8-BrPETcGMPS for a further 5 min before ACh stimulation. Stimulation with ACh induced a biphasic increase in the frequency of exocytotic events. The frequencies of the initial and late phases were 6.5 Ϯ 0.5 and 0.8 Ϯ 0.2 events·cell , n ϭ 8) (Fig. 4B) . In addition, in the presence of PKI, Rp-8-BrPETcGMPS added at 4 min from the start of ACh stimulation did not increase the frequency of exocytotic events (Fig. 4B) . The treatment of PKIamide abolished the delayed and transient increase in the frequency of the late phase induced by the addition of Rp-8-BrPETcGMPS.
Effects of BAY-60-7550 (a PDE2 inhibitor) on Ca 2ϩ
-regulated exocytosis. The results of the PKI-amide experiments suggest that Rp-8-BrPETcGMPS accumulates cAMP, which leads to the delayed, but transient, increase in the frequency of the late phase. In antral mucous cells, Rp-8-BrPETcGMPS may inhibit PDE2, which degrades cAMP to 5=-AMP. We examined the effects of BAY-60-7550 on the frequency of ACh-stimulated exocytotic , n ϭ 6) (Fig. 5A) . BAY-60-7550 added at 4 min from the start of ACh stimulation also transiently increased the frequency of exocytotic events. The frequency of the late phase 1.5 min after the BAY-60-7550 addition was 3.8 Ϯ 0.4 events·cell
Ϫ1
·30 s
Ϫ1 (n ϭ 6) (Fig. 5B) . In antral mucous cells, BAY-60-7550 induced the delayed and transient increase in the frequency of the late phase. Thus, BAY-60-7550 mimicked the effects of Rp-8-BrPETcGMPS.
The cAMP content. Figure 6 shows changes in the cAMP contents of the stripped antral mucosae. Stimulation with ACh alone induced little changes in the cAMP contents of the stripped antral mucosae. The cAMP content before ACh stimulation was 9.9 Ϯ 0.8 pmol/g dry tissue (n ϭ 3), and those 1, 5, and 10 min from the start of ACh stimulation were 11.6 Ϯ 1.3 (n ϭ 3), 11.1 Ϯ 1.6 (n ϭ 3), and 9.3 Ϯ 0.3 (n ϭ 4) pmol/g dry tissue, respectively. However, the addition of Rp-8-BrPETcGMPS plus ACh gradually increased cAMP contents of the stripped antral mucosae, and the cAMP contents reached a plateau within 5 min. The cAMP content before the addition was 9.7 Ϯ 1.9 pmol/g dry tissue (n ϭ 3), and those 1, 5, and 10 min from the start of the addition were 12.7 Ϯ 0.9 (n ϭ 3), 17.7 Ϯ 1.6 (n ϭ 3), and 17.1 Ϯ 1.5 (n ϭ 5) pmol/g dry tissue, respectively. Thus, the addition of Rp-8-BrPETcGMPS plus ACh increased the cAMP contents of the stripped antral mucosae by 73% within 5 min and maintained cAMP contents increased until 10 min from the start of the addition. However, the addition of Rp-8-BrPETcGMPS plus ACh did not increase cAMP contents at 1 min after the addition. The addition of BAY-60-7550 plus ACh, instead of Rp-8-BrPETcGMPS plus ACh, also increased cAMP contents of the stripped antral mucosae to 17.3 Ϯ 2.3 pmol/g dry tissue (n ϭ 3, 10 min from the start of the addition). The addition of DMSO (vehicle control) did not increase cAMP contents of the stripped antral mucosae (10.7 Ϯ 2.2 pmol/g dry tissue, n ϭ 5, 10 min after the DMSO addition).
The PGE 2 released. We measured the amount of PGE 2 released from the stripped antral mucosae for 15 min during ACh stimulation (Table 1 ). In the control experiments (DMSO addition), the amount of PGE 2 released from the stripped antral mucosae for 15 min was 0.18 Ϯ 0.04 g/g tissue (n ϭ 3). Stimulation with 1 M ACh did not increase the amount of PGE 2 released from the stripped antral mucosae (0.21 Ϯ 0.09 g/g tissue, n ϭ 3), whereas stimulation with 10 M ACh increased it to 0.52 Ϯ 0.13 g/g tissue (n ϭ 3). Thus, 1 M ACh stimulation induced no increase in the amount of PGE 2 released from the antral mucosae, whereas 10 M ACh stimulation induced a significant increase in it. Similar results have already been reported in the previous report (17) .
Expression and localization of PDE2 in antral mucous cells. We examined the expression of PDE2 in antral mucosae using Western blot analysis. The PDE2A band was detected at the molecular mass of about 105 kDa in the antral mucosa of guinea pigs (data not shown). As a positive control, we examined PDE2A in the brain. The PDE2A band was also detected at about 105 kDa (data not shown).
Next, the localization of PDE2 was examined by immunohistochemistry. Figure 7 , A1, B1, and C1, shows the micrographs of antral mucosa, and Fig. 7, A2, B2 , and C2, shows antral mucous cells. The HE staining showed that antral mucous cells are located in the upper part (1/3 to 1/2) of the antral gland columns (Fig. 7,  A1 and A2) . Antral mucous cells were immunopositively stained for PDE2A (Fig. 7, B1 and B2) . A high-magnification view revealed that the cytoplasm of antral mucous cells was immunopositively stained for PDE2A (Fig. 7, C1 and C2) .
Effects However, the transient increase induced by the inhibition of PDE2 occurred in the late phase, not in the initial phase. The experiments of Rp-8-BrPETcGMPS showed that Rp-8-BrPETcGMPS has a very rapid effect on the mechanism responsible for this delayed and transient increase in the frequency of the ACh-stimulated exocytotic events, that is, the 3.5-min latency with prolonged exposure cannot be the result of a cumulative effect of Rp-8-BrPETcGMPS. This study also showed that, in the presence of Rp-8-BrPETcGMPS, ACh induces a gradual increase in the cAMP contents. At present, we do not know why the cAMP accumulation by 1 M ACh stimulation is slow in the antral mucous cells. There are some possibilities, such as a low activity of adenylate cyclases or a high activity of cAMP-degrading enzymes except PDE2. Fur- ther studies will be needed to clarify why the rate of cAMP accumulation is slow.
In antral mucous cells, stimulation with 10 M ACh increases [Ca 2ϩ ] i and activates an autocrine mechanism via PGE 2 (16) . This autocrine mechanism stimulates cAMP accumulation via the EP4 PGE 2 receptor and induces a significant increase in the frequency of the initial phase (16) . However, this study demonstrated that 1 M ACh minimally stimulates cAMP accumulation and that PKI-amide has little effects on the frequency of the initial phase stimulated by 1 M ACh. Moreover, 1 M ACh induced no increase in the amount of PGE 2 released, whereas 10 M ACh induced a significant increase in it. Thus, 1 M ACh does not cause an increase in cAMP via the PGE 2 autocrine mechanism. The previous studies demonstrated that an increase in [Ca 2ϩ ] i stimulated by 10 M ACh is much larger than that stimulated by 1 M ACh (4, 14 -16) . A high concentration of [Ca 2ϩ ] i during 10 M ACh stimulation may activate cyclooxygenase (COX) 1, which produces PGE 2 in antral mucous cells (16) . The accumulation of cGMP, and not cAMP, plays an important role for maintaining the frequency of the Ca 2ϩ -regulated exocytotic events in antral mucous cells stimulated with 1 M ACh.
However, antral mucosae still released PGE 2 under the basal condition. PGE 2 released under the basal condition may activate the PGE 2 autocrine mechanism. Our previous study demonstrated that, in antral mucosae, PGE 2 released under the basal condition are from nonepithelial cells via COX2, those during ACh stimulation are from epithelial cells via COX1, and that, in isolated epithelial cells, the amount of PGE 2 released under the basal condition is negligibly small (17) . Because we used isolated antral mucous cells for observing exocytosis, the amount of PGE 2 released under the basal condition is negligibly small. Thus, PGE 2 is unlikely to be released from antral mucous cells under the basal condition, indicating that the PGE 2 autocrine mechanism is inactive in the basal condition.
This study demonstrated that 1 M ACh stimulates cGMP accumulation in antral mucous cells and that cGMP accumulation increases the frequency of the initial phase in Ca 2ϩ -regulated exocytotic events. However, it remains unknown how antral mucous cells accumulate cGMP. In many cell types, nitric oxide (NO) induced accumulation of cGMP (1, 8, 24) . NO is also known to be a mucosal defense factor in the stomach. In antral mucous cells, NO may stimulate cGMP accumulation. Nitric oxide synthase (NOS) is known to be a Ca 2ϩ -dependent enzyme. An increase in the [Ca 2ϩ ] i by ACh stimulation may stimulate the activity of NOS, leading to NO/cGMP accumulation.
On the other hand, our previous study demonstrated that AA stimulates peroxisome proliferation activation receptor-␣ (PPAR␣), which increases the frequency of Ca 2ϩ -regulated exocytosis in antral mucous cells (4, 15) . Some reports have shown that AA and PPARs stimulate NO production in many tissues and cells (7, 13, 15, 19, 21, 22) . AA has been reported to stimulate cGMP accumulation via NO production in vascular smooth muscle cells (9) . A similar pathway may stimulate cGMP accumulation in antral mucous cells. Further studies are required to clarify the pathway stimulating cGMP accumulation in antral mucous cells.
In conclusion, Rp-8-BrPETcGMPS inhibited PDE2 in antral mucous cells, leading to cAMP accumulation by inhibiting cAMP degradation. This accumulation of cAMP induced the delayed, but transient, increase in the frequency of the Ca 2ϩ -regulated exocytotic events. This study suggests that the accumulation of cGMP, and not cAMP, plays an important role for continuous mucin secretion by maintaining a low frequency of the late phase in Ca 2ϩ -regulated exocytosis during a mild ACh stimulation, such as during sleep.
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